Bryan Bunn, MD
Family Medicine · Edenton, NCNPI 1568787141
Payments from drug & device makers
Across 272 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Boehringer Ingelheim$580
- AbbVie$503
- Pfizer$289
- Lilly USA, LLC$219
- Sanofi-aventis U.S. LLC$150
- plus $1K from 26 others
What the payments were for
- Food & beverage$4,171100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 76 | $1,077 |
| Boehringer Ingelheim | 40 | $580 |
| AbbVie(2 entities) | 31 | $503 |
| Pfizer | 18 | $289 |
| Lilly USA, LLC | 13 | $219 |
| Sanofi-aventis U.S. LLC | 10 | $150 |
| Novartis | 8 | $145 |
| Merck | 10 | $124 |
| Johnson & Johnson(2 entities) | 8 | $122 |
| AstraZeneca | 9 | $119 |
| Amgen | 6 | $95 |
| Abbott | 5 | $94 |
| Bioventus LLC | 3 | $87 |
| E.r. Squibb & Sons, L.L.C. | 5 | $76 |
| Idorsia Pharmaceuticals US Inc | 3 | $55 |
| GSK | 3 | $55 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| Exact Sciences | 3 | $49 |
| Astellas Pharma US Inc | 2 | $45 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 3 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Upsher-smith Laboratories LLC | 1 | $17 |
| Cranial Technologies, Inc | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Dynavax Technologies Corporation | 1 | $16 |
| Biocryst US Sales Co., LLC | 1 | $15 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
| Hartmann USA, Inc. | 1 | $13 |
| Avanos Medical | 1 | $13 |
| Eisai Inc. | 1 | $12 |
How this compares
$4,171 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 188 | $164,305 |
| JardianceEmpagliflozin | 131 | $138,933 |
| OzempicSemaglutide | 94 | $128,152 |
| TrulicityDulaglutide | 77 | $107,298 |
| XareltoRivaroxaban | 72 | $72,546 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 52 | $65,589 |
| MounjaroTirzepatide | 47 | $51,705 |
| SynjardyEmpagliflozin/Metformin Hcl | 44 | $35,050 |
| MyrbetriqMirabegron | 62 | $29,936 |
| FarxigaDapagliflozin Propanediol | 21 | $29,298 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $21,744 |
| Tresiba Flextouch U-200Insulin Degludec | 40 | $21,215 |
| JanuviaSitagliptin Phosphate | 23 | $21,198 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $20,100 |
| TradjentaLinagliptin | 28 | $19,197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Tradjenta, Jentadueto | $580 | $220,738228 claims |
| PfizerEliquis | $289 | $164,305188 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $219 | $159,004124 claims |
| Novo NordiskOzempic | $1,077 | $128,15294 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Multaq | $150 | $77,95865 claims |
| Johnson & JohnsonXarelto | $122 | $72,54672 claims |
| MerckJanuvia, Janumet Xr, Belsomra | $124 | $50,56877 claims |
| AstraZenecaFarxiga, Symbicort | $119 | $32,48933 claims |
| Astellas Pharma US IncMyrbetriq | $45 | $29,93662 claims |
| AbbVieLinzess, Synthroid | $503 | $19,735102 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $55 | $19,35931 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Edenton
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.